drugset / Trial / NCT00314353
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
Phase 2
Terminated
7 enrolled
NSABP Foundation Inc
Genentech, Inc. · collabHoffmann-La Roche · collabInternational Drug Development Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.
Timeline
- Start
- 2006-03
- Primary completion
- 2008-05
- Completion
- 2010-06
Outcome
Outcome not reported
Stopped (Enrollment): “The study was closed early due to low enrollment and new information regarding the benefit of the study regimen.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 650 mg/m2 | Oral |
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |